Drug Profile
Nartograstim
Alternative Names: hG-CSF - Kyowa Hakko; KW 2228; Marograstim; Naltograstim; Neu-upLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Yakult Honsha
- Class Chemoprotectants; Granulocyte colony-stimulating factors
- Mechanism of Action Granulocyte macrophage colony stimulating factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Leucopenia; Neutropenia
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Japan (Parenteral)
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin
- 31 Dec 1994 Launched for Neutropenia in Japan (Injection)